Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]
HC Wainwright Reiterates Buy Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Insider Selling: Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) CEO Sells $5,307,931 20 in Stock etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 5,220,000 shares, a growth of 6.3% from the March 31st total of 4,910,000 shares. Based on an average trading volume of 802,900 shares, the days-to-cover ratio […]
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Sees Significant Growth in Short Interest themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.